- Published at
- by manilatimes.net
mixed
mixed
News for Reata Pharmaceuticals, Inc. (RETA)
- Published at
- by gurufocus.com
positivepositiveBiogen (BIIB) Surpasses Q3 Earnings Expectations Amid Cost Reductions and Strong Drug Performance
Biogen (BIIB) reported third-quarter financial results that exceeded expectations, driven by ongoing cost reduction measures and robust performance of its new A- Published at
- by globenewswire.com
mixedmixedGlobal Corporate Wellness Market to Surpass ~USD 117 Billion by 2030 | DelveInsight
The growing demand for corporate wellness is largely driven by factors such as increased screen time, higher workloads, rapid urbanization, poor diet,...- Published at
- by globenewswire.com
mixedmixedFriedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report
Friedreich’s Ataxia Drugs Gaining Prominence Amid Several Government Initiatives Focused on Rare Disease Research....- Published at
- by seekingalpha.com
mixedmixedQuince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX)
Quince’s transformation is complete with the acquisition of EryDel in October 2023. Check out the reasons why I rate QNCX stock as a Strong Buy.- Published at
- by globenewswire.com
mixedmixedGlobal Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight
The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...- Published at
- by globenewswire.com
mixedmixedBIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating...- Published at
- by globenewswire.com
mixedmixedSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the...- Published at
- by globenewswire.com
mixedmixedMONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB)...- Published at
- by globenewswire.com
mixedmixedINVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB)...- Published at
- by marketscreener.com
mixedmixedVera Therapeutics Appoints Christy J. Oliger to Board of Directors
BRISBANE, Calif., June 11, 2024 -- Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with...- Published at
- by globenewswire.com
mixedmixedLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments...- Published at
- by globenewswire.com
positivepositiveSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, RETA, VRTV, HCCI
NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the...- Published at
- by investing.com
mixedmixedU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.50% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.50%TRVV.BATRVC34.SATRV.MXTRVTROWT1RO34.SARETAPA9.DENWL.MXNWLINTC.SNINTC.MXINTCINL.DEINCO.BRDISH.MXDISHD1IS34.SACSCO.MXCSCOCIS.DECIS.BRAURCUAURC4333.HK0R03.L0KNY.L0K7J.L0IBG.LTNXP0A4T.LWGBA34.SAWBA.MXWBA.BAWBAW8A.DESNBRMSFT.SNMSFT.MXMSFTMSF.DEMSF.BRMHK.MXMHKM1HK34.SALYV.MXLYVGMMVFENPH.MXENPH3LN.DE0QYE.L0LSZ.L0K2F.L0JVD.L- Published at
- by investing.com
neutralneutralReata Pharma Appoints Rajiv Patni as EVP and Chief Research & Development Officer By Investing.com
Reata Pharma Appoints Rajiv Patni as EVP and Chief Research & Development Officer- Published at
- by marketscreener.com
mixedmixedReata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Reata Pharmaceuticals, Inc. , a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv... | June 13, 2023- Published at
- by marketscreener.com
positivepositiveBioPharma Credit inks loan agreement with Reata Pharmaceuticals
BioPharma Credit PLC on Thursday announced that it has entered into a definitive senior secured loan agreement with Reata Pharmaceuticals Inc, a Plano, Texas-based pharmaceutical company. Under the... | May 11, 2023- Published at
- by globenewswire.com
mixedmixedChronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
Chronic kidney disease (CKD) is a debilitating condition that affects people all over the world, and it is one of a small number of non-communicable...- Published at
- by seekingalpha.com
mixedmixedBiopharma Exposure In SVB Financial Group And Investor Strategy (NASDAQ:SIVB)
Here's a long list of biopharmas exposed to SVB. Many of these deposits will be uninsured. Click here to see which companies may be affected.- Published at
- by globenewswire.com
mixedmixedChronic Kidney Disease (CKD) Drugs Market Size Worth US$ 19.8 billion by 2030 - Growth Plus Reports
Newark, New Castle, USA, March 16, 2023 (GLOBE NEWSWIRE) -- According to the deep-dive market assessment study by Growth Plus Reports, the global chronic...ZEG.DETKPHFTAKP34.SATAKN.MXTAKRETAREGN34.SAREGN.MXREGNPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFEKSPHFJNJGSK.LGSKGS7.DEGLAXFFGEN.MXFGENDJNJ3.BADJNJ2.BAAZNN.MXAZNCFAZN.LAZNARDXAMGN.MXAMGN.BAAMGNAMG.DEAKBAABBV34.SAABBV.MXABBV.BAABBV4AB.DE4547.T4502.T4502.S0R2M.L0IL8.L0A87.L0A4J.LNVSN.MXNVSEFNVSD.BANVSNOVN.SWN1VS34.SA0K9E.L